Contact SCGE
Your email
Message
Send
SCGE Consortium Home
About SCGE TCDC
Contact Us
License
Home
Gene Therapy Trial Browser
Clinical Trial Report
Gene Therapy Trial Report
Summary
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
NCTID
NCT05444894
(View at clinicaltrials.gov)
Description
The purpose of this study is to evaluate the safety, tolerability, and efficacy of treatment with EDIT-301 in adult participants with Transfusion Dependent beta Thalassemia
(Show More)
Development Status
Inactive
Indication
Beta-Thalassemia Major
Disease Ontology Term
DOID:0080771
Compound Name
EDIT-301
Compound Alias
Renizgamglogene autogedtemcel
Sponsor
Editas Medicine, Inc.
Funder Type
Industry
Recruitment Status
Active not recruiting
Enrollment Count
9
Results Posted
Not Available
Therapy Information
Target Gene/Variant
HBG1/HBG2
Therapy Type
Gene editing
Therapy Route
Ex-vivo
Mechanism of Action
Overexpression of protective allele/gene
Route of Administration
Intravenous
Drug Product Type
Autologous cells
Target Tissue/Cell
CD34+ cells
Delivery System
Viral transduction
Vector Type
LV
Editor Type
ASCas12a mRNA
Dose 1
Min: 5.7E6 CD34+ cells/kg
Dose 2
Max: 11.9E6 CD34+ cells/kg
Dose 3
Dose 4
Dose 5
Study Record Dates
Current Stage
Phase1, Phase2
Submit Date
2022-06-27
Completion Date
2025-12
Last Update
2025-04-02
Participation Criteria
Eligible Age
18 Years - 35 Years
Standard Ages
Adult
Sexes Eligible for Study
ALL
Locations
No.of Trial Sites
8
Locations
Canada,United States
Regulatory Information
Has US IND
True
FDA Designations
Regenerative Medicine Advanced Therapy
Recent Updates
Ended development of this program due to inability to locate a financial partner
Resources/Links
Clinical Publications
Reni-cel, the first AsCas12a gene-edited cell therapy, led to hemoglobin normalization and increased fetal hemoglobin in severe sickle cell disease patients in an interim analysis of the RUBY trial
News and Press Releases
(Poster) Reni-cel, the first AsCas12a gene-edited cell therapy, shows promising preliminary results in key clinical outcomes in transfusion-dependent β-thalassemia patients treated in the EdiThal trial - EHA 2024
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
Related NCTID
Long Term Follow-Up: NCT06363760